Most health plans aren't using value frameworks to decide which prescription drugs they will cover, or how much to pay for them.
That's according to a new report from Washington, D.C.-based health care consulting comapny Avalere, which said that health plans are instead waiting for the frameworks to evolve and for physicians to buy in before they base decisions on them.
The framework initiative was launched in mid-2015 by the American Society of Clinical Oncology, Institute for Clinical and Economic Review, Memorial Sloan Kettering, and National Comprehensive Care Network as a means of helping stakeholders assess the value of drugs.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
